United Kingdom

In the UK, our lawyers are supporting the companies building an economy of the future. Our offices in London, Cambridge and Liverpool keep us close to our clients in the technology, life sciences, healthcare, real estate and finance sectors.

Our international teams work across Europe, Asia and North America to help our clients when and where they need it most, be that keeping you up to date on evolving regulatory challenges, guiding you through your international transactions, or helping resolve disputes.

Our four offices across the UK give us great coverage and the ability to advise our clients regardless of their location.

Experience

Success in high profile claim against a FTSE 250 Financial Services company

Acting successfully to resolve a high-profile dispute for breach of contract involving a mainstay of the FTSE 250.

Richard Viegas

Canada Life on a £101 million five-year real estate loan

advised Canada Life Asset Management on a £101.15 million loan to PATRIZIA AG, a leading partner for global real assets, for a fund it manages on behalf of a South Korean pension fund.

Press release

Olivia Briggs

Advising Jagex on its sale

Long-standing client Jagex, one of the UK’s largest video game developers and publishers, on its sale to The Carlyle Group. The transaction positions Jagex for continued growth in the global gaming market, building upon its existing 300 million players accounts and $1bn RuneScape franchise.

Press release

Robert Fenner

Richard Faichney

Alex Walker

See full team Hide full team

Acquisition of OXGENE by WuXi AppTec

Global pharmaceutical company WuXi AppTec on its acquisition of OXGENE, a pioneering United Kingdom-based contract research and development (R&D) organisation that designs and develops scalable gene therapy technologies.

Press release

Marianna Vlas

Inflexion Private Equity

Advising Inflexion Private Equity on the sale of portfolio group, Glide.

Press release

James Goold

Suzy Davis

Glenmark Pharma on the sale of its portfolio of CNS products in Poland to Neuraxpharm

Glenmark Pharma on its divestment of its CNS business in Poland including its portfolio of generics and branded generics products and the transfer of its commercial team in Poland to private equity backed Neuraxpharm, a specialty pharmaceutical company focused on the treatment of CNS disorders.

Press release